Its architect's daughter has cystic fibrosis—and benefits from a "miracle drug" backed by an agency he's attacking.

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Kristen Ambrose, Senior Vice President and Chief Accounting Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotechnology company with strong financial health according ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408.Maximize Your Portfolio with Data ...